
    
      -  Screening to admission: up to 21 days

        -  Admission to the end of the follow-up: up to 41 days

             -  Period 1: Treatment period of 15 days with ATRIPLA™ (background therapy). Patients
                should receive the same regimen and dose of ATRIPLA™ during the all study screening
                and period 1.

             -  Period 2: Treatment over a period of 21 days in co-administration with rifapentine.

             -  Follow up: 3 to 5 days after the last rifapentine administration.
    
  